Innoviva (INVA) Gross Margin (2011 - 2026)
Innoviva's (INVA) quarterly Gross Margin came in at 77.39% in Q1 2026, down 533.0% YoY from 17.87% in Q1 2025, and down 1.03% on a QoQ basis from 78.19% in Q3 2025.
Innoviva (INVA) Gross Margin (2011 - 2026) Analysis & Trends
Innoviva (INVA) has 9 years of Gross Margin data on file, last reported at 77.39% in Q1 2026.
- Quarterly Gross Margin fell 533.0% year-over-year to 77.39% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 93.59% (down 198.0% YoY) and the FY2025 annual result came in at 74.8%, down 778.0% from the prior year.
- Gross Margin slipped to 77.39% in Q1 2026, from 78.19% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 2409.3% in Q1 2024 to a low of 217.62% in Q2 2023.
- A 5-year average of 237.77% and a median of 82.91% in 2025 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2024 — Gross Margin soared 239593 bps — and 2025, when it slumped 232658 bps.
- Tracing INVA's Gross Margin over 5 years: stood at 98.61% in 2022, then gained by 1 bps to 99.29% in 2023, then declined by 18 bps to 81.71% in 2024, then slipped by 4 bps to 78.19% in 2025, then decreased by 1 bps to 77.39% in 2026.
- The last three Gross Margin figures came in at 77.39% (Q1 2026), 78.19% (Q3 2025), and 82.91% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 90.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 89.76% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 60,631,834.75% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 76.90% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 84.20% |
| 10 | Innoviva | 1.54 Bn | 968.79 Mn | 90.62 Mn | 75.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 75.77% |
| Mar 31, 2026 | 77.39% |
| Sep 30, 2025 | 78.19% |
| Jun 30, 2025 | 82.91% |
| Mar 31, 2025 | 82.72% |
| Sep 30, 2024 | 81.71% |
| Jun 30, 2024 | 85.07% |
| Mar 31, 2024 | 2,409.30% |
| Sep 30, 2023 | 99.29% |
| Jun 30, 2023 | -217.62% |
| Mar 31, 2023 | 13.37% |
| Sep 30, 2022 | 98.61% |
| Jun 30, 2022 | 100.00% |
| Mar 31, 2022 | 100.00% |
| Sep 30, 2021 | 100.00% |
| Mar 31, 2014 | 75.90% |
| Mar 31, 2013 | 100.00% |
| Dec 31, 2011 | 100.00% |
| Sep 30, 2011 | 100.00% |
| Jun 30, 2011 | 81.58% |